Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

NCT03541694 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 622

Last updated 2019-03-26

No results posted yet for this study

Summary

This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.

Conditions

  • Yellow Fever

Interventions

BIOLOGICAL

Stamaril®

Routine vaccination with Stamaril yellow fever vaccine

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Pasteur, a Sanofi Company

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2018-05-30
Completion
2018-05-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03541694 on ClinicalTrials.gov